Trial over Pfizer's Zoloft gets underway; Aurobindo selling Australian unit;

@FiercePharma: ICYMI from FiercePharmaManufacturing: Chinese drugmaker to build $60M API plant. News | Follow @FiercePharma

@EricPFierce: Supply chain slip results in expired Pfizer birth control pills being sold in Canada. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Eisai to shed 450 jobs as it pares down U.S. workforce by one-fourth. News | Follow @CarlyHFierce

> Aurobindo is selling its Australian subsidiary to Eris Pharma for an undisclosed sum to focus on sales in the U.S., emerging markets and Europe. Report

> A federal trial that will test whether a jury believes that pregnant women taking Pfizer's ($PFE) Zoloft risked having babies with heart defects has gotten underway in St. Louis. Story

> Walgreens Boots Alliance Inc. ($WBA) will close 200 Walgreens drugstores in the U.S. to cut another $500 million in costs. Story

> Biocon has gotten approval in Mexico to sell its Glargine diabetes drug. Story

Medical Device News

@FierceMedDev: Biocartis joins forces with Microbiome for quick sepsis test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA finalizes accelerated approval pathway for critical devices, aims to get med tech to market faster. Article | Follow @VarunSaxena2

@EmilyWFierce: Diagnosing Winnie the Pooh characters from the DSM. Just your typical Friday. | Follow @EmilyWFierce

> Pryor Medical gears up for rollout of military-inspired catheter. More

> Report: Demise of NeuroControl a cautionary tale of 'Orphan Markets' for devicemakers. Story

> Startup receives $20M in funding to test its leadless pacemaker. Article

Biotech News

@FierceBiotech: EuroBiotech: Woodford: It's a bubble, Pfizer-backed IO player plans IPO, UniQure cashes in on Bristol deal. More | Follow @FierceBiotech

@JohnCFierce: Eisai cuts follow GlaxoSmithKline, Amgen, Merck, Sanofi, Pfizer, AstraZeneca, Shire, etc... Over 4 months. More | Follow @JohnCFierce

@DamianFierce: ICYMI: The thrilling conclusion to #FierceMadness and why I've had "One Shining Moment" stuck in my head all day. Winner | Follow @DamianFierce

> Safety scare with AstraZeneca's diabetes drug could shake up the DPP-4 field. News

> Carbylan pulls off a $65M IPO on its second go-round. Article

> Shire's billion-dollar eye drug gets in line for a speedy FDA review. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.